Zentiva announce that it have extended strategic partnership with Adalvo, signing a licensing deal for three molecules, within Europe. The products are indicated in a variety of therapeutical areas like Respiratory, CNS and Dermatology.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.26 RON | +0.62% | +1.24% | +11.64% |
1st Jan change | Capi. | |
---|---|---|
+11.64% | 493M | |
+21.59% | 44.15B | |
+23.03% | 23.02B | |
+18.22% | 15.33B | |
+12.26% | 13.74B | |
+52.55% | 12.16B | |
-10.02% | 6.84B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+12.92% | 5.66B |
- Stock Market
- Equities
- SCD Stock
- News Zentiva S.A.
- Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology